Mohammad Jad Moussa: ASCO24 Proceedings – GTA as a Nephron-Sparing ‘Bridging’ Strategy

Mohammad Jad Moussa, Postdoc Fellow of GU Oncology at MD Anderson Cancer Center, shared a post on X:

“From ASCO24 Proceedings: GTA as a Nephron-Sparing ‘Bridging‘ Strategy Before Cisplatin-Based Regimens in Metastatic UC.

Matt Campbell and  Omar Alhalabi at MD Anderson Cancer Center GUSM.

Joint Work with terrific residents at UTHealth Houston IM Residency, BCM IM Residency.

• Why: ADCs not accessible to all patients, chemo data remains crucial for many patients and oncologists.
• Who: n=76, 1L LA/mUC, 63% prior nephrostomy/ureteral stenting, 72% started on GTA due to tumor-related renal insufficiency.
• What: High GFR +11.2 mL/min [95% CI, 7.4-14.9] with GTA, 23% (16/69) received cisplatin post-GTA, mOS 11.3 months.”

Visit the article website.
Source: Mohammad Jad Moussa/X